Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride (A3008) is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, exhibiting IC₅₀ values of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2, with >200-fold selectivity against other kinases (ApexBio, product page)[1]. It disrupts Rho-mediated stress fiber formation and modulates both cell cycle progression and cytokinesis[1]. Y-27632 is widely validated for enhancing stem cell viability, reducing smooth muscle proliferation, and inhibiting tumor invasion in vitro and in vivo[1,2]. The compound’s solubility profile and stability parameters support flexible experimental design[1]. Benchmarking studies confirm its reproducible effects in translational workflows, especially for stem cell and cancer models[2].

Biological Rationale

The Rho/ROCK signaling pathway regulates actin cytoskeleton dynamics, cell migration, and proliferation[1]. Dysregulation of this pathway is implicated in cancer progression, abnormal smooth muscle contraction, and impaired stem cell survival[1]. Selective inhibition of ROCK1/2 enables precise dissection of Rho-mediated events without broadly affecting unrelated kinases, allowing for targeted studies in cytoskeletal biology, oncology, and regenerative medicine[1,2]. Y-27632 dihydrochloride provides a robust platform for investigating the mechanisms underlying tumor invasion, stem cell maintenance, and tissue morphogenesis[2,3].

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as a competitive inhibitor of the ATP-binding site on ROCK1 and ROCK2, selectively suppressing kinase activity at nanomolar concentrations (IC₅₀: 140 nM for ROCK1; K_i: 300 nM for ROCK2)[1]. The compound exhibits >200-fold selectivity over kinases such as PKC, PKA, MLCK, and PAK, minimizing off-target effects[1]. By blocking ROCK-mediated phosphorylation of downstream targets, Y-27632 disrupts actin stress fiber formation, modulates focal adhesion dynamics, and inhibits myosin light chain activation[1,4]. This results in altered cell morphology, reduced contractility, and enhanced cell survival under stress[1,2]. In proliferative contexts, Y-27632 modulates cell cycle progression from G1 to S phase and interferes with cytokinesis, affecting cell proliferation and tissue organization[1].

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM, showing >200-fold selectivity over other kinases such as PKC or PKA (ApexBio, product page)[1].
• It disrupts Rho-mediated actin stress fiber formation and focal adhesion assembly in multiple cell types (Y-27632: Precision ROCK Inhibition in Cancer Research)[4].
• Y-27632 enhances survival and viability of human induced pluripotent stem cells (iPSCs) post-thaw and during passaging, supporting pluripotency and differentiation capacity (Ni et al., 2022)[2].
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (ApexBio, product page)[1].
• In vivo, Y-27632 suppresses tumor invasion and metastasis, reducing pathological structures in murine models (Y-27632: Advancing Translational Research)[5].
• Stock solutions are stable for several months at <-20°C, and the compound is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, supporting diverse assay formats (ApexBio, product page)[1].

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used for:

• Enhancing viability and cloning efficiency of pluripotent and multipotent stem cells after dissociation[2].
• Dissecting cytoskeletal reorganization in migration and adhesion assays[1,4].
• Suppressing smooth muscle cell proliferation and contraction in vitro[1].
• Reducing tumor invasion and metastasis in preclinical animal models[5].
• Studying Rho/ROCK signaling in neuronal, cardiac, and epithelial cells[2,4,5].

For a broader discussion of translational applications, see Precision ROCK Inhibition: Guiding Translational Research; this article provides updated quantitative solubility and selectivity data, and clarifies optimal workflow integration for stem cell and cancer models.

For troubleshooting and emerging workflow strategies, see Harnessing Y-27632 Dihydrochloride: Mechanistic Precision; the current article extends these insights with new iPSC viability data and consolidated benchmarking.

Common Pitfalls or Misconceptions

• Y-27632 is not effective as an inhibitor for kinases outside the ROCK family (e.g., PKC, PKA, MLCK, PAK) due to high selectivity[1].
• Long-term storage of prepared solutions is not recommended; stability is best preserved as a solid at ≤4°C, desiccated[1].
• The compound does not directly induce pluripotency but supports survival and expansion of existing stem cell lines[2].
• Use in clinical or therapeutic contexts is not validated; Y-27632 is for research use only[1].
• Solubility may require warming to 37°C or use of an ultrasonic bath; incomplete dissolution can affect dosing accuracy[1].

Workflow Integration & Parameters

Y-27632 dihydrochloride is formulated as a solid and should be stored desiccated at ≤4°C or below. For stock solutions, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Warming to 37°C or ultrasonic treatment enhances solubility. Store aliquots of stock solutions below -20°C for up to several months; avoid repeated freeze-thaw cycles. Working concentrations typically range from 1–10 μM for most cell-based assays[1]. For iPSC workflows, add Y-27632 during dissociation and early culture to improve survival[2]. For cancer invasion and migration assays, pre-treat target cells 30–60 minutes prior to endpoint analysis[5]. Consistent dosing and control experiments are critical for reproducibility.

Conclusion & Outlook

Y-27632 dihydrochloride is a benchmark tool for selective ROCK1/2 inhibition in cytoskeletal, stem cell, and cancer research. Its high potency, selectivity, and robust performance in both in vitro and in vivo systems make it a preferred reagent for dissecting Rho/ROCK signaling mechanisms. Ongoing advances in stem cell and tumor biology continue to expand the scope of Y-27632 applications. For detailed product specifications or to order, see the Y-27632 dihydrochloride A3008 kit page.

References:
[1] ApexBio product documentation: https://www.apexbt.com/y-27632-dihydrochloride.html
[2] Ni, P., et al. (2022). Generation and characterization of human-derived iPSC lines from two cousins with schizophrenia and bipolar disorder and their unaffected cousin. Stem Cell Research, 63, 102832. https://doi.org/10.1016/j.scr.2022.102832
[3] Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cyt..., https://y27632.com/index.php?g=Wap&m=Article&a=detail&id=16549
[4] Y-27632 Dihydrochloride: Precision ROCK Inhibition in Can..., https://y27632.com/index.php?g=Wap&m=Article&a=detail&id=16560
[5] Y-27632 Dihydrochloride: Advancing Translational Research..., https://m6412.com/index.php?g=Wap&m=Article&a=detail&id=16417